Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH-399A Phase 1 in Healthy Volunteers
NCT06088784Phase 1Completed
- Sponsor
- HanAll Biopharma
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ath-399a in Parkinson's disease (PD) (12 arms), sponsored by HanAll Biopharma. Primary endpoints: Treatment-Emergent Adverse Events, Participants With at Least 1 Treatment-Emergent Adverse Event and 12 more. Started Sep 2023; status: completed.
02
Drugs
ath-399a
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06088784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088784.